These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7759734)

  • 21. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group.
    Wall TC; Califf RM; Blankenship J; Talley JD; Tannenbaum M; Schwaiger M; Gacioch G; Cohen MD; Sanz M; Leimberger JD
    Circulation; 1994 Jul; 90(1):114-20. PubMed ID: 8025985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of perfluorotributylamine/pluronic F-68 stem-emulsion (FC43se) against reperfusion injury in ischemic rabbit lungs.
    Ueno T; Matsuura Y; Wada S; Murakami H; Kajihara H
    Transplant Proc; 1997; 29(1-2):1349-53. PubMed ID: 9123336
    [No Abstract]   [Full Text] [Related]  

  • 23. Myocardial oxygen supply under critical conditions, the effects of hemodilution and fluorocarbons.
    Fennema M; Erdmann W; Faithfull NS
    Adv Exp Med Biol; 1992; 317():527-44. PubMed ID: 1288170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluosol-DA as a red-cell substitute in acute anemia.
    N Engl J Med; 1986 Dec; 315(26):1677-8. PubMed ID: 3785341
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia.
    Kolodgie FD; Dawson AK; Roden DM; Forman MB; Virmani R
    Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of postischemic reperfusion cardiac injury with a perfluorochemical solution.
    Parrish MD; Olson RD; Mushlin PS; Artman M; Boucek RJ
    J Cardiovasc Pharmacol; 1984; 6(1):159-64. PubMed ID: 6199599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits.
    Rempf C; Standl T; Schenke K; Chammas K; Gottschalk A; Burmeister MA; Gottschalk A
    Br J Anaesth; 2009 Oct; 103(4):496-504. PubMed ID: 19710071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical experience of hemodilution with fluosol-DA (author's transl)].
    Fukushima K; Nakamura M; Takemura R
    Masui; 1981 Jul; 30(7):741-5. PubMed ID: 7321165
    [No Abstract]   [Full Text] [Related]  

  • 30. [Possibility of the use of perfluorochemicals (fluorocarbons) as adjuvants in chemotherapy of cancer].
    Kuwamura K; Kokunai T
    Gan To Kagaku Ryoho; 1982 Jul; 9(7):1256-61. PubMed ID: 7184453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of perfluorocytylbromide emulsions on a cardioplegic model of reperfusion injury.
    Zhao L; Smith JR; Eyer CL
    Proc West Pharmacol Soc; 1992; 35():77-80. PubMed ID: 1502244
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale for the clinical studies of anemia treated with the perfluorochemical emulsion: Fluosol DA 20%.
    Tremper KK
    Prog Clin Biol Res; 1983; 122():307-13. PubMed ID: 6348785
    [No Abstract]   [Full Text] [Related]  

  • 33. [Protective effect of fluosol-DA in acute cerebral ischemia (author's transl)].
    Ishikawa R; Peerless SJ; Hunter IG
    No Shinkei Geka; 1981 Dec; 9(13):1503-8. PubMed ID: 6808409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%.
    Cleman M; Jaffee CC; Wohlgelernter D
    Circulation; 1986 Sep; 74(3):555-62. PubMed ID: 2943533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluosol: therapeutic failure in severe anemia.
    Kale PB; Sklar GE; Wesolowicz LA; DiLisio RE
    Ann Pharmacother; 1993 Dec; 27(12):1452-4. PubMed ID: 8305774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.
    Swann KW; Ropper AH; Zervas NT
    Prog Clin Biol Res; 1983; 122():399-404. PubMed ID: 6348787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function.
    Schaer GL; Hursey TL; Abrahams SL; Buddemeier K; Ennis B; Rodriguez ER; Hubbell JP; Moy J; Parrillo JE
    Circulation; 1994 Dec; 90(6):2964-75. PubMed ID: 7994844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological study and clinical application of fluorocarbon artificial blood].
    Zhang RA; Xiong RC; Su BJ
    Zhonghua Wai Ke Za Zhi; 1985 Jul; 23(7):395-8, 443-4. PubMed ID: 4053861
    [No Abstract]   [Full Text] [Related]  

  • 39. Identification of a time window for therapy to reduce experimental canine myocardial injury: suppression of neutrophil activation during 72 hours of reperfusion.
    Simpson PJ; Fantone JC; Mickelson JK; Gallagher KP; Lucchesi BR
    Circ Res; 1988 Dec; 63(6):1070-9. PubMed ID: 2461814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of controlled reperfusion after ischemia. XIX. Reperfusate composition: benefits of blood cardioplegia over fluosol DA cardioplegia during regional reperfusion--importance of including blood components in the initial reperfusate.
    Acar C; Partington MT; Buckberg GD
    J Thorac Cardiovasc Surg; 1991 Feb; 101(2):284-93. PubMed ID: 1992239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.